Results for "Liquidia Corporation"

Liquidia Corporation is projected to have over 50% upside potential, driven by a favorable Yutrepia ruling and the possibility of a buyout.

Liquidia Corporation aims to achieve at least $1 billion in net revenue by 2027, driven by a 44% sequential increase in Q1 net product sales for its drug YUTREPIA.

Wells Fargo has increased its price target for Venture Global (VG) from $10 to $14, citing specific reasons for the upgrade.

The article assesses whether Liquidia Corporation (LQDA) is a good stock to consider buying for investment purposes.

Several companies, including Biodesix, Baldwin Insurance Group, CNA Financial, and Leidos, have announced their latest financial results or declared dividends. Other firms like Liquidia Corporation and Descartes have set dates for their upcoming earnings reports.

Liquidia Corporation held its Q4 earnings call, providing key financial and operational updates for the quarter.

Liquidia Corporation released a summary of its first-quarter 2026 earnings call, detailing its financial performance for the period.

Billionaire investor Tom Steyer has reportedly increased his holdings in several companies, including tech giants like Microsoft and Amazon, and various pharmaceutical firms. His recent investment activities indicate a bullish outlook on these specific stocks.

Liquidia Corporation's stock sees a boost following the overturning of a district court patent ruling, indicating a favorable legal development for the company.